Expression of perforin and granzyme-B in peripheral blood lymphocyte in patients with prostate cancer and the clinical significance.
10.11817/j.issn.1672-7347.2015.04.008
- Author:
Jingliang HE
1
;
Liuxun LI
;
Wensu WEI
;
Jingchao WEI
;
Zhi LONG
;
Yichuan ZHANG
;
Leye HE
Author Information
1. Department of Urology, Th ird Xiangya Hospital, Central South University, Changsha 410013, China.
- Publication Type:Journal Article
- MeSH:
Case-Control Studies;
Granzymes;
metabolism;
Humans;
Lymphocytes;
enzymology;
Male;
Perforin;
metabolism;
Prostatic Hyperplasia;
Prostatic Neoplasms;
immunology
- From:
Journal of Central South University(Medical Sciences)
2015;40(4):387-391
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the expression of perforin and granzyme-B in peripheral blood lymphocyte (PBL) in patients with prostate cancer (PCa) and the clinical significance.
METHODS:The expressions of perforin and granzyme-B in PBL were detected by fluorescence quantitative reverse transcription polymerase chain reaction. The results of perforin and granzyme-B expression were compared among patients with PCa (n=60), patients with BPH (benign prostatic hyperplasia, n=40) and healthy controls (n=20).
RESULTS:Th e expressions of perforin and granzyme-B in patients with PCa were significantly lower than that in patients with BPH or that in the healthy controls (P<0.05), respectively. Furthermore, in PCa patients with low pathological grade, the expressions of perforin and granzyme-B in PBL was statistically higher than that in patients with high pathological grade (P<0.05). The expressions of perforin and granzyme-B in PCa patients at high clinical stage was statistically lower than that in PCa patients at low clinical stage (P<0.05).
CONCLUSION:The results of this study suggest that development and progression of PCa might be associated with poor immune status of patients.
